Pre-Open Stock Movers:

Soleno Therapeutics, Inc. (NASDAQ: SLNO) 49% LOWER; announced top-line results from the Companys Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS). The study did not meet its primary endpoint of change from baseline in hyperphagia. The change was measured by the total score of a Hyperphagia Questionnaire for Clinical Trials (HQ-CT, 036). An improvement in HQ-CT is represented by a decrease in the score. The mean (SE) change from baseline for DCCR was -5.94 (0.879) and for placebo was -4.27 (1.145). The least squares mean difference in HQ-CT score of DCCR compared with placebo was -1.67 (1.294); 95% confidence interval (-4.24, 0.89); p=0.1983.

Chesapeake Energy (NYSE: CHK) 48.2% LOWER; Said to Prepare Chapter 11 Filing, Giving Lenders Control - Bloomberg

Nikola Corporation (Nasdaq: NKLA) 19.9% HIGHER; sees continued momentum after gaining 103% on Monday.

Cerecor Inc. (Nasdaq: CERC) 14% LOWER; intends to offer for sale shares of its common stock in an underwritten public offering.

REV Group (NYSE: REVG) 11.1% LOWER; Credit Suisse downgraded from Neutral to Underperform with a price target of $6.00 (from $5.00).

The Lovesac Company (NASDAQ: LOVE) 10% HIGHER; reported Q1 EPS of ($0.58), $0.09 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $54.4 million versus the consensus estimate of $47.18 million.

Macy's (NYSE: M) 9% HIGHER; Announcing $4.5 Billion in Financing

MoneyGram International, Inc. (NASDAQ: MGI) 8.4% HIGHER; reported 100% year-over-year digital transaction growth in May a significant acceleration from the first quarter of 2020 where the company reported 57% growth.

Tailored Brands (NYSE: TLRD) 7.2% HIGHER;, owner of Men's Wearhouse and Jos. A Bank, is considering bankruptcy, according to Bloomberg, citing people with knowledge of the matter.

OPKO Health Inc. (NASDAQ: OPK) 7% HIGHER; Following last Octobers announcement of successful results of the global Phase 3 study of once-weekly somatrogon, an investigational agent for the treatment of pediatric growth hormone deficiency (pGHD), OPKO Health Inc. (NASDAQ: OPK) announced today that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN® (somatropin) for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-naïve Japanese pre-pubertal children with GHD. The findings were consistent with the results previously reported in the Phase 3 global study.

Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) 6.4% HIGHER; announces that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial. Amphastars newly approved drug product was determined by the FDA to be therapeutically equivalent to Quelicin (Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial) distributed in the United States by Pfizer, Inc. Succinylcholine Chloride Injection is for intramuscular and intravenous use. It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

ContraFect Corp. (NASDAQ: CFRX) 5.6% HIGHER; Cantor Fitzgerald initiates coverage onwith a Overweight rating and a price target of $15.00.

Stitch Fix (NASDAQ: SFIX) 4.7% LOWER; reported Q3 EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $371.7 million versus the consensus estimate of $406.66 million.

Coupa Software (NASDAQ: COUP) 4.4% LOWER; reported Q1 EPS of $0.20, $0.13 better than the analyst estimate of $0.07. Revenue for the quarter came in at $119.2 million versus the consensus estimate of $111.51 million.

The Scotts Miracle-Gro Company (NYSE: SMG) 4% HIGHER; announced increased sales and earnings guidance based on higher demand in both its U.S. Consumer and Hawthorne segments.

Retrophin, Inc. (NASDAQ: RTRX) 3.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions.

Casey's General Stores (NASDAQ: CASY) 2.7% LOWER; reported Q4 EPS of $1.67, $0.12 worse than the analyst estimate of $1.79. Revenue for the quarter came in at $1.81 billion versus the consensus estimate of $1.76 billion. Fiscal 2021 Guidance - Due to the continued uncertainty of COVID-19, guidance for the fiscal year ending April 30, 2021 will not be provided at this time. This will be reevaluated as conditions warrant.

Mesa Laboratories, Inc. (NASDAQ: MLAB) 2.4% LOWER; announced that it has commenced an underwritten public offering of $100 million of shares of its common stock

Extreme Networks (NASDAQ: EXTR) 2.1% HIGHER; Director, John Shoemaker, bought 50,000 shares on 06/05 at $5.11.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) 1.7% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the companys first-in-class pyruvate kinase-R (PKR) activator mitapivat for the treatment of patients with thalassemia. Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.